Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

June Lee, MD

Key Takeaway: Dr. June Lee has been a member of the Board of Directors at Eledon Pharmaceuticals since December 2020. She has held significant positions in various biotech firms, including serving as CEO of Esker Therapeutics and Chief Development Officer at MyoKardia, contributing to its acquisition by Bristol Myers Squibb. Dr. Lee has a strong academic background and is involved in several advisory boards and councils.
Price reaction · baseline $1.37 (2023-09-29 close) · 6 other ELDN headline(s) in the window, move may be shared
day 0 close
+13.1%
day 1
+12.4%
day 3 · peak
+17.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Lee has extensive experience in biotechnology and pharmaceuticals.
  • She played a key role in the successful acquisition of MyoKardia.
  • Her leadership in various organizations showcases her influence in the field.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Dr. Lee has served as a member of the Board of Directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) since December 2020. From February 2021 to November 2021, Dr. Lee was founder and Chief Executive Officer at Esker Therapeutics, Inc. From January 2017 until June 2020, Dr. Lee was Chief Development Officer and Chief Operating Officer of MyoKardia, Inc., a clinical stage biotechnology company with a focus on precision cardiovascular medicines. At MyoKardia she built and led a world class development organization culminating in the company’s $13.1 billion acquisition by Bristol Myers Squibb in November 2020. Prior to MyoKardia, Dr. Lee was Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator at UCSF for early-stage technologies in therapeutics, devices, diagnostics, and digital health. She is also the founding chair of the University of California Drug, Device, Discovery and Development Group. Previously, she was therapeutic area head in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. Dr. Lee is a member of the Board of Directors of the Council of Korean Americans, of which she previously served as Chair. She is a founding member of the Translational Research Advisory Council of South Korea’s MOGAM Research Institute, and the MTRAC for Life Sciences Innovation Hub Therapeutic/Diagnostic Oversight Committee, a unit associated with the University of Michigan Medical School. She is a Board Director for Abivax, CinCor Pharma, GenEdit and Tenaya Therapeutics, serves on Johns Hopkins University Center for Therapeutic Translation’s Advisory Board, and on the Scientific Advisory Board for Foresite Labs. Dr. Lee completed a Bachelor of Science in chemistry at the Johns Hopkins University, an M.D. at the School of Medicine at University of California, Davis, and her clinical training in internal medicine and pulmonary & critical care at UCLA and UCSF.

Frequently Asked Questions

What positions has Dr. June Lee held?

Dr. Lee has served as CEO of Esker Therapeutics and held roles at MyoKardia.

What is Dr. Lee's educational background?

She holds a Bachelor of Science in chemistry and an M.D. from UC Davis.

What role did Dr. Lee play at MyoKardia?

She was Chief Development Officer and contributed to its acquisition by Bristol Myers Squibb.

Is Dr. Lee involved in any advisory boards?

Yes, she serves on several advisory boards, including at Johns Hopkins University.

Last updated: Oct 1, 2023